LMAT Earnings Date: Nov 4, 2026 (Estimated) — LeMaitre Vascular, Inc.
NASDAQ · Healthcare · Medical Instruments & Supplies
Updated
When is LMAT's next earnings date?
LeMaitre Vascular, Inc. (LMAT) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.69 on revenue of $67.4M.
How did LMAT do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), LeMaitre Vascular, Inc. posted EPS of $0.74 versus the $0.81 estimate, a miss of 8.6%. Revenue was $70.4M against a $71.5M estimate. The stock's 1-day post-earnings move was -25.3%.
How much does LMAT stock move after earnings?
LMAT beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.8% (up or down) in the day after earnings.
About LeMaitre Vascular, Inc.
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | 0.81 | 0.74 | -8.64% | $70.4M | ❌ Miss | -25.32% | -21.69% | -22.51% |
| 2026-05-05 | Q1 2026 | 0.66 | 0.68 | +3.03% | $66.6M | ✅ Beat | -1.59% | -13.20% | -16.26% |
| 2026-02-25 | Q4 2025 | 0.67 | 0.68 | +1.49% | $64.5M | ✅ Beat | +24.42% | +16.46% | +21.02% |
| 2025-11-06 | Q3 2025 | 0.57 | 0.75 | +31.58% | $61.0M | ✅ Beat | +1.43% | +4.72% | -2.89% |
| 2025-08-05 | Q2 2025 | 0.57 | 0.60 | +5.26% | $64.2M | ✅ Beat | +8.92% | +10.25% | +13.63% |
| 2025-02-27 | Q4 2024 | 0.49 | 0.49 | +0.00% | $55.7M | ➖ Inline | -8.06% | -17.43% | -16.67% |
| 2024-10-31 | Q3 2024 | 0.43 | 0.49 | +13.95% | $54.8M | ✅ Beat | +7.35% | +14.35% | +19.51% |
| 2024-08-01 | Q2 2024 | 0.47 | 0.53 | +12.77% | $55.8M | ✅ Beat | -1.44% | -3.85% | +4.89% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q3 FY25 · $57.7M total
| Segment | Share | Revenue | YoY | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 59.9% | $34.6M | — | — | — | — | — |
| Other Countries | 25.7% | $14.8M | — | — | — | — | — |
| GERMANY | 7.8% | $4.5M | — | — | — | — | — |
| CANADA | 6.6% | $3.8M | — | — | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.